Literature DB >> 23527816

SAR based design of nicotinamides as a novel class of androgen receptor antagonists for prostate cancer.

Su Hui Yang1, Chin-Hee Song, Hue Thi My Van, Eunsook Park, Daulat Bikram Khadka, Eun-Yeung Gong, Keesook Lee, Won-Jea Cho.   

Abstract

Molecular knowledge of pure antagonism and systematic SAR study offered a direction for structural optimization of DIMN to provide nicotinamides as a novel series of AR antagonists. Nicotinamides with extended linear scaffold bearing sterically bulky alkoxy groups on isoquinoline end were synthesized for H12 displacement. AR binding affinity and molecular basis of antiandrogenic effect establish the optimized derivatives, 7au and 7bb, as promising candidates of second generation AR antagonists for advanced prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527816     DOI: 10.1021/jm3014103

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  A new compound targets the AF-1 of androgen receptor and decreases its activity and protein levels in prostate cancer cells.

Authors:  Tuyen Thanh Tran; Chin-Hee Song; Kyung-Jin Kim; Keesook Lee
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Design and Synthesis of 4-(4-Benzoylaminophenoxy)phenol Derivatives As Androgen Receptor Antagonists.

Authors:  Ayumi Yamada; Shinya Fujii; Shuichi Mori; Hiroyuki Kagechika
Journal:  ACS Med Chem Lett       Date:  2013-08-19       Impact factor: 4.345

3.  Optimisation of tetrahydroisoquinoline-based chimeric microtubule disruptors.

Authors:  Wolfgang Dohle; Mathew P Leese; Fabrice L Jourdan; Christopher J Chapman; Ernest Hamel; Eric Ferrandis; Barry V L Potter
Journal:  ChemMedChem       Date:  2014-05-12       Impact factor: 3.466

4.  A widely distributed metalloenzyme class enables gut microbial metabolism of host- and diet-derived catechols.

Authors:  Vayu Maini Rekdal; Paola Nol Bernadino; Michael U Luescher; Sina Kiamehr; Chip Le; Jordan E Bisanz; Peter J Turnbaugh; Elizabeth N Bess; Emily P Balskus
Journal:  Elife       Date:  2020-02-18       Impact factor: 8.140

Review 5.  Androgen receptor: structure, role in prostate cancer and drug discovery.

Authors:  M H Eileen Tan; Jun Li; H Eric Xu; Karsten Melcher; Eu-leong Yong
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

Review 6.  Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance.

Authors:  Xiaohong Tian; Yang He; Jinming Zhou
Journal:  Front Pharmacol       Date:  2015-03-24       Impact factor: 5.810

Review 7.  Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer.

Authors:  Nada Lallous; Kush Dalal; Artem Cherkasov; Paul S Rennie
Journal:  Int J Mol Sci       Date:  2013-06-14       Impact factor: 5.923

8.  Discovery of Isoquinolinoquinazolinones as a Novel Class of Potent PPARγ Antagonists with Anti-adipogenic Effects.

Authors:  Yifeng Jin; Younho Han; Daulat Bikram Khadka; Chao Zhao; Kwang Youl Lee; Won-Jea Cho
Journal:  Sci Rep       Date:  2016-10-03       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.